The World Health Organization (WHO) estimates that more than 1.5 billion people are affected by neglected tropical diseases (NTDs) and a further two billion are threatened by these diseases. If left
Tuberculosis is the most common infectious disease worldwide. In 2022 alone, there were 10.6 million new infections and 1.3 million deaths. The European-African network PanACEA—a consortium of
The interdisciplinary project DEFENDER is developing innovative approaches to combat (re-)emerging viruses.The project, coordinated by the Leibniz Institute of Virology (LIV), is being funded with
Antimicrobial resistance (AMR) is one of the greatest challenges for global health and development. According to estimates by the World Health Organisation (WHO), almost five million deaths worldwide
EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive vaccine against diseases caused by the Epstein-Barr virus (EBV)
Microorganisms produce a wide variety of natural products that can be used as active agents to treat diseases such as infections or cancer. The blueprints for these molecules can be found in the
On the occasion of World AIDS Day on 1 December 2024, the International Antiviral (formerly AIDS) Society-USA (IAS-USA) has published new international guidelines for the treatment and prevention of
The development of an effective vaccine against the hepatitis C virus has been an enormous challenge for decades due to the high genetic diversity of the virus. The research team led by DZIF scientist
Two DZIF junior scientists—Prof Philipp Schommers and Dr Alexander Simonis—have been honoured with silver medals by the Walter Siegenthaler Society for their fundamental medical research in the field
Eleven scientists from the German Center for Infection Research (DZIF) are among the “Highly Cited Researchers 2024”. The ranking, published on 19 November by the company Clarivate Analytics, lists
